IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs

Head-To-Head Studies Are Few, But Data Could Change Positioning

Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.

IBD on a blue background with medical neon icons, medical background with a microscope, science, research — Payer preferences in IBD could shuffle as new data emerge • Source: Shutterstock

A slate of new mechanisms are emerging in inflammatory bowel disease (IBD), and with new ulcerative colitis (UC) and Crohn’s Disease (CD) data and products emerging in the space, change may be coming to payer formularies dominated by anti-TNF antibodies and other biologics used as advanced therapies after patients progress on initial conventional therapies.

Companies that already have multiple IBD products on the market, including Humira (adalimumab) marketer AbbVie Inc., may be able to negotiate rebates in the US not just for a single UC or CD product, but for a bundle of treatments, giving them an edge in payer negotiations

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

16 May 2025

• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

16 May 2025

• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

15 May 2025

• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

14 May 2025

• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

19 May 2025

• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.